Oxford Biomedica company signage on brick building exterior

MARKET TRENDS

19 Mar 2026

Gene Therapy’s Next Hotspot? Look to Australia

Oxford Biomedica licenses key platforms to VVMF, boosting gene therapy manufacturing across Asia-Pacific

FDA headquarters sign displayed outside regulatory agency building

INSIGHTS

16 Mar 2026

New Viral Vector Strategy Targets Brain Cancer

Siren Biotechnology receives the first FDA clearance for an AAV-based cancer trial, targeting aggressive glioblastoma with a viral vector ...

Robotic lab pipette dispensing liquid into sample vials

PARTNERSHIPS

10 Mar 2026

Gene Therapy Deal Aims to Speed Blindness Cure

Genezen and Atsena join forces to manufacture AAV gene therapies for inherited retinal diseases as ATSN-201 moves toward a planned 2028 re...

Cleanroom technician in protective suit inside pharmaceutical manufacturing facility

MARKET TRENDS

19 Feb 2026

AAV Arms Race: Who Controls Gene Therapy’s Future?

As AAV demand surges, biotech firms race to lock in manufacturing capacity, reshaping alliances and competition across gene therapy

Automated biotech instrument performing AAV analytics

INNOVATION

11 Feb 2026

NanoMosaic Win Highlights Manufacturing’s New Frontier

FDA nod to NanoMosaic’s Nanoneedle tech signals analytics as the new frontier in AAV manufacturing

Automated biomanufacturing facility with control panels and cleanroom layout

MARKET TRENDS

5 Feb 2026

The Race to Modernize Viral Vector Production

Automation and consolidation are reshaping viral vector manufacturing, forcing producers to modernize early to stay competitive and reliab...

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.